Dmk Pharmaceuticals Quick Ratio (DMK) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Dmk Pharmaceuticals Corporation  (NASDAQ: DMK)

Dmk Pharmaceuticals's Quick Ratio

DMK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Dmk Pharmaceuticals's Cash & cash equivalent grew by 894.1 % in the Q3 2023 sequentially, while Current Liabilities decreased, this led to improvement in Dmk Pharmaceuticals's Quick Ratio to 0.5, Quick Ratio remained below Dmk Pharmaceuticals Corporation average.

Within Major Pharmaceutical Preparations industry 482 other companies have achieved higher Quick Ratio than Dmk Pharmaceuticals in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 2887, from total ranking in the second quarter 2023 at 3457.

Explain Quick Ratio?
How much Cash & cash equivalents DMK´s has?
What are DMK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DMK Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 65.48 % 50.91 % -7.47 % -10.24 % -11.95 %
Y / Y Cash & cash equivalent Change 171.99 % -92.47 % -82.41 % -95.22 % -91.48 %
Quick Ratio MRQ 0.5 0.05 0.25 0.1 0.3
DMK's Total Ranking # 2887 # 3457 # 2574 # 4165 # 2354
Seq. Current Liabilities Change -8.69 % 16.76 % 16.94 % 32.73 % -16.73 %
Seq. Cash & cash equivalent Change 894.1 % -78.58 % 181.61 % -54.64 % -72.49 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 483
Healthcare Sector # 903
Overall Market # 2887


Quick Ratio Statistics
High Average Low
5 1.18 0
(Mar 31 2015)   (Dec 31 2012)




Financial Statements
Dmk Pharmaceuticals's Current Liabilities $ 13 Millions Visit DMK's Balance sheet
Dmk Pharmaceuticals's Cash & cash equivalent $ 7 Millions Visit DMK's Balance sheet
Source of DMK's Sales Visit DMK's Sales by Geography


Cumulative Dmk Pharmaceuticals's Quick Ratio

DMK's Quick Ratio for the trailling 12 Months

DMK Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 18.47 % 3.62 % -14.66 % -24.64 % -30.22 %
Y / Y Cash & cash equivalent TTM Growth -77.91 % -90.65 % -85.88 % -79.9 % -60.94 %
Quick Ratio TTM 0.23 0.16 0.38 0.72 1.21
Total Ranking TTM # 4048 # 3234 # 4004 # 3908 # 2954
Seq. Current Liabilities TTM Growth 11.5 % 12.03 % -2.41 % -2.83 % -2.47 %
Seq. Cash & cash equivalent TTM Growth 57.24 % -52.8 % -48.46 % -42.25 % -33.43 %

Quick ratio ranking by company, industry and sector >> Back to DMK Financial Strength Comparisons >> Go to Compare DMK Quick Ratio to its Competitors

On the trailing twelve months basis DMK Cash & cash equivalent more than doubled by 171.99 % in Q3 2023 year on year, faster than Current Liabilities, this led to increase in in Dmk Pharmaceuticals's Quick Ratio to 0.23, Quick Ratio remained below DMK average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 538 other companies have achieved higher Quick Ratio than Dmk Pharmaceuticals. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3234 to 4048.

Explain Quick Ratio?
How much Cash & cash equivalents DMK´s has?
What are DMK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 539
Healthcare Sector # 1087
Within the Market # 4048


trailing twelve months Quick Ratio Statistics
High Average Low
2.73 1.27 0.15
(Dec 31 2021)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Transcode Therapeutics Inc   1.35 $ 7.565  Millions$ 5.598  Millions
Universe Pharmaceuticals Inc  1.35 $ 18.504  Millions$ 13.754  Millions
Addex Therapeutics Ltd  1.34 $ 4.599  Millions$ 3.442  Millions
2seventy Bio Inc   1.33 $ 90.226  Millions$ 68.008  Millions
Cytomx Therapeutics Inc   1.32 $ 194.110  Millions$ 146.790  Millions
Scisparc Ltd  1.32 $ 2.076  Millions$ 1.571  Millions
Elicio Therapeutics Inc   1.29 $ 14.841  Millions$ 11.486  Millions
Rigel Pharmaceuticals Inc  1.29 $ 62.351  Millions$ 48.273  Millions
Evotec Se  1.27 $ 662.556  Millions$ 520.322  Millions
Puma Biotechnology Inc   1.26 $ 85.029  Millions$ 67.362  Millions
Gyre Therapeutics Inc   1.25 $ 2.228  Millions$ 1.783  Millions
Oramed Pharmaceuticals Inc  1.23 $ 125.626  Millions$ 102.362  Millions
Organogenesis Holdings Inc   1.21 $ 98.226  Millions$ 81.482  Millions
Kyntra Bio Inc   1.20 $ 251.340  Millions$ 209.415  Millions
Amphastar Pharmaceuticals Inc   1.17 $ 302.076  Millions$ 257.963  Millions
Longeveron Inc   1.16 $ 3.933  Millions$ 3.394  Millions
Biodexa Pharmaceuticals Plc  1.15 $ 8.147  Millions$ 7.097  Millions
Aeon Biopharma inc   1.14 $ 16.177  Millions$ 14.177  Millions
Intercept Pharmaceuticals inc   1.13 $ 102.736  Millions$ 90.845  Millions
Enveric Biosciences Inc   1.10 $ 4.267  Millions$ 3.883  Millions
Zoetis Inc   1.09 $ 1,754.000  Millions$ 1,608.000  Millions
Durect Corp  1.06 $ 38.985  Millions$ 36.752  Millions
Nature s Sunshine Products inc   1.04 $ 76.036  Millions$ 73.312  Millions
Calliditas Therapeutics Ab  1.04 $ 104.676  Millions$ 100.997  Millions
Skye Bioscience Inc   1.04 $ 14.211  Millions$ 13.719  Millions
Aquestive Therapeutics Inc   1.04 $ 24.917  Millions$ 24.057  Millions
Abbott Laboratories  1.03 $ 7,047.000  Millions$ 6,809.000  Millions
Xencor Inc  0.99 $ 52.733  Millions$ 53.041  Millions
Kineta Inc   0.99 $ 7.562  Millions$ 7.615  Millions
Avadel Pharmaceuticals Plc  0.99 $ 52.641  Millions$ 53.138  Millions

Date modified: 2026-09-26T07:01:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.